Latest News

  • Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia Read More
  • Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Read More
  • Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Read More

Investors

Learn More

Working at Alkermes

Join Our Team